Literature DB >> 6461995

Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.

S Jeppsson, S Gershagen, E D Johansson, G Rannevik.   

Abstract

The aim of the study was to evaluate the functional state of the hypothalamo-pituitary-gonadal axis and to assess the concentrations of MPA in the peripheral blood during very long-term use of depo-medroxyprogesterone acetate (DMPA) as a contraceptive agent. The concentrations of MPA, sex-hormone binding globulin (SHBG) and the different pituitary and gonadal hormones in the peripheral blood were measured in nine 26-41 year old women. They had for 4.4-10.6 years (mean 8.9 years) been receiving DMPA im in a dose of 150 mg every 12th week as a contraceptive. Blood samples were obtained immediately before an injection of DMPA, 2 weeks later, and again immediately before the next injection. SHBG was measured by radio-electro-immunoassay; MPA, gonadal and pituitary hormones by RIA. The investigation showed that the oestradiol levels - even after very long-term use of DMPA - were still within the normal range for the early follicular phase. Gonadotrophins and prolactin were within the normal range for eumenorrhoeic women as well as the concentration of SHBG. MPA did not accumulate in the plasma. The changes in the plasma levels of oestradiol, MPA and SHBG after each injection disappeared within 12 weeks. The study appearts to warrant the conclusion that even up to 10 years' use of DMPA in a dose of 150 mg im every 12th week as a contraceptive agent, does not induce hormonal changes different from those seen after the very first injection.

Entities:  

Keywords:  Androgens; Biology; Contraception; Contraceptive Agents, Female--analysis; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--analysis; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--analysis; Contraceptive Agents--side effects; Contraceptive Methods; Depo-provera--side effects; Endocrine System; Estradiol--analysis; Estrogens; Estrone--analysis; Family Planning; Follicle Stimulating Hormone--analysis; Gonadotropins; Gonadotropins, Pituitary; Hormones; Injectables; Luteinizing Hormone--analysis; Medroxyprogesterone Acetate--analysis; Physiology; Pituitary Hormones; Prolactin--analysis; Testosterone--analysis

Mesh:

Substances:

Year:  1982        PMID: 6461995     DOI: 10.1530/acta.0.0990339

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  20 in total

1.  Depot medroxyprogesterone acetate use and periodontal health in 15- to 44-year-old US females.

Authors:  L Susan Taichman; Woosung Sohn; Giselle Kolenic; Maryfran Sowers
Journal:  J Periodontol       Date:  2012-02-06       Impact factor: 6.993

Review 2.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

3.  Depot medroxyprogesterone acetate administration alters immune markers for HIV preference and increases susceptibility of peripheral CD4+ T cells to HIV infection.

Authors:  Carley Tasker; Amy Davidow; Natalie E Roche; Theresa L Chang
Journal:  Immunohorizons       Date:  2017-11-01

Review 4.  Injectable contraception with depot medroxyprogesterone acetate. Current status.

Authors:  Andrew M Kaunitz; Allan Rosenfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Depot-medroxyprogesterone acetate and endothelial function before and after acute oral, vaginal, and transdermal estradiol treatment.

Authors:  Britta N Torgrimson; Jessica R Meendering; Paul F Kaplan; Christopher T Minson
Journal:  Hypertension       Date:  2011-02-28       Impact factor: 10.190

6.  Commentary on Tosun et al. (2019): Dynamic changes in sex hormones and smoking cessation.

Authors:  MacKenzie R Peltier; Sherry A McKee
Journal:  Addiction       Date:  2019-07-25       Impact factor: 6.526

7.  Differential metabolism of clinically-relevant progestogens in cell lines and tissue: Implications for biological mechanisms.

Authors:  Salndave B Skosana; John G Woodland; Meghan Cartwright; Kim Enfield; Maleshigo Komane; Renate Louw-du Toit; Zephne van der Spuy; Chanel Avenant; Donita Africander; Karl-Heinz Storbeck; Janet P Hapgood
Journal:  J Steroid Biochem Mol Biol       Date:  2019-02-26       Impact factor: 4.292

8.  The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.

Authors:  Léanie Kleynhans; Nelita Du Plessis; Nasiema Allie; Muazzam Jacobs; Martin Kidd; Paul D van Helden; Gerhard Walzl; Katharina Ronacher
Journal:  Infect Immun       Date:  2013-02-04       Impact factor: 3.441

9.  Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Authors:  Chelsea B Polis; Sharon L Achilles; Zdenek Hel; Janet P Hapgood
Journal:  Contraception       Date:  2017-12-11       Impact factor: 3.375

10.  Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.

Authors:  Irina A Zalenskaya; Neelima Chandra; Nazita Yousefieh; Xi Fang; Oluwatosin E Adedipe; Suzanne S Jackson; Sharon M Anderson; Christine K Mauck; Jill L Schwartz; Andrea R Thurman; Gustavo F Doncel
Journal:  J Clin Invest       Date:  2018-09-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.